Dijon

• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• DASSOH - Systematic use of DDAVP to prevent serum sodium overcorrection in severe hyponatremia : a multicenter open-label randomized control … Recruiting
  2023-507254-32-00 5 2024-12-17 Severe hyponatremia and a high risk of rapid SNa overcorrection
• Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejectio … Recruiting
  2023-503602-37-00 5 2024-12-16 Cardiogenic Shock
• REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemoth … Recruiting
  2024-516709-22-00 10 2024-12-16 metastatic colorectal cancer carcinoma
• Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit … Recruiting
  2024-510981-18-00 5 2024-12-12 Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is o
• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 4 2024-12-10 Diffuse cutaneous systemic sclerosis (dcSSc)
• A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting
  2024-516109-21-00 5 2024-12-09 Polycythaemia Vera (PV)
• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation … Recruiting
  2024-517408-12-00 5 2024-11-28 Patient in end-stage renal disease candidate for a kidney transplant
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Multicentre randomised double-blind superiority trial with a roll-over phase to evaluate the efficacy of OM-89 vs placebo in reducing antibi … Recruiting
  2024-512595-35-00 5 2024-11-21 neurogenic bladder
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Pati … Recruiting
  2024-511313-38-00 4 2024-11-17 Soft Tissue Sarcoma
• MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting
  2023-507776-42-00 5 2024-11-14 Non-small cell lung cancer
• Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical … Recruiting
  2024-514886-21-00 6 2024-11-06 Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (P
• Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting
  2024-516242-19-00 5 2024-11-05 lupus nephritis
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 Triple negative breast cancer
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re … Recruiting
  2022-502972-22-00 5 2024-10-31 Clostridioides difficile infection.
• A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i … Recruiting
  2024-514899-41-00 4 2024-10-31 Breast cancer
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• LENVABLA Lenvatinib in neo-adjuvant and adjuvant therapy for poor-prognosis BCLC A HepatoCellular Carcinoma treated by percutaneous ablatio … Recruiting
  2024-514606-31-00 4 2024-10-29 Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eli
• QUIDOSE. Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary s … Recruiting
  2024-516101-23-00 5 2024-10-28 Sarcoidosis
• Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting
  2023-510429-14-00 4 2024-10-22 HER2-mutated or overexpressed/amplified solid tumours

Showing 289–312 of 813 trials